-
2024-515089-15-00
5
2025-02-28
active non-infectious uveitis (intermediate uveitis, posterior uveitis
-
2022-502878-16-00
5
2025-01-23
Acute ischemic strokes with incomplete reperfusion
-
2024-514046-37-00
5
2025-01-16
HIV-1 Infection
-
2024-514228-18-00
4
2025-01-16
Asthma in adults who remain uncontrolled despite medium to high dose I
-
2024-511738-11-00
5
2024-12-18
Psoriatic arthritis
-
2024-513208-32-00
5
2024-12-16
Chronic Spontaneous Urticaria
-
2024-515389-15-00
4
2024-12-13
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like epis
-
2023-508891-12-00
4
2024-11-28
Diabetic retinopathy
-
2024-511202-23-00
4
2024-10-31
Epithelial ovarian cancer that progressed on prior PARP inhibitor ther
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2024-515936-62-00
9
2024-10-10
Patients with advanced or metastatic gastrointestinal (GI) tumors.
-
2024-516212-24-00
4
2024-10-08
Chronic Myeloid Leukemia
-
2023-507749-27-00
6
2024-08-16
Hemophilia A
-
2023-505673-32-00
5
2024-08-05
Hypophosphatasia
-
2023-510561-10-00
4
2024-07-19
Cardiovascular illness, Intensive care unit (ICU), open-heart surgery
-
2023-505608-43-00
4
2024-07-04
Moderate to Severe Hidradenitis Suppurativa
-
2023-510378-14-00
3
2024-06-20
modulation of the innate immune system in healthy subjects
-
2023-503666-23-00
5
2024-06-07
Neovascular age-related macular degeneration
-
2023-506054-20-00
5
2024-06-05
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
-
2023-509026-21-00
6
2024-06-03
severe asthma
-
2022-502991-21-00
4
2024-05-22
Lichen planus
-
2022-502099-22-01
5
2024-04-29
HIV-1 Infection
-
2022-502518-98-00
5
2024-04-26
nonsegmental vitiligo
-
2023-505722-33-00
4
2024-04-15
cholangiocarcinoma or gallbladder carcinoma